Table 2 Subgroup analysis of pooled HRs for OS in cancer patients with abnormal expression level of CXCL5
From: Prognostic significance of CXCL5 expression in cancer patients: a meta-analysis
Subgroup analysis | No. of cohorts | Pooled HRs | Meta regression (p value) | Heterogeneity | |
|---|---|---|---|---|---|
Random | I2 (%) | p value | |||
Sample size | Â | Â | 0.602 | Â | Â |
 < 100 | 8 | 1.60 [0.81–3.17] | – | 70.9 | 0.001 |
 ≥ 100 | 9 | 1.69 [1.37–2.08] | – | 62.0 | 0.007 |
Type of cancer | Â | Â | 0.197 | Â | Â |
 Digestive system carcinoma | 10 | 1.78 [1.39–2.28] | – | 45.3 | 0.058 |
 Non-digestive system carcinoma | 7 | 1.59 [1.09–2.31] | – | 64.0 | 0.011 |
Follow-up time | Â | Â | 0.204 | Â | Â |
 < 100 | 10 | 1.75 [1.32–2.32] | – | 69.6 | 0.001 |
 ≥ 100 | 7 | 1.60 [1.07–2.39] | – | 58.6 | 0.024 |
Samples detected | Â | Â | 0.186 | Â | Â |
 Blood | 3 | 1.90 [1.31–2.76] | – | 0.0 | 0.680 |
 Tissue | 14 | 1.65 [1.28–2.12] | – | 69.8 | 0.000 |
NOS score | Â | Â | 0.526 | Â | Â |
  ≥ 7 | 12 | 1.71 [1.36–2.15] | – | 49.6 | 0.026 |
 < 7 | 5 | 1.82 [1.10–2.99] | – | 57.2 | 0.053 |
Source of HR | Â | Â | 0.209 | Â | Â |
 Directly | 10 | 1.61 [1.24–2.09] | – | 72.2 | 0.000 |
 Indirectly | 7 | 1.91 [1.27–2.88] | – | 38.6 | 0.134 |